SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes

被引：0
|
作者：
Irene Fernández-Ruiz
机构：
[1] Nature Reviews Cardiology,
来源：
Nature Reviews Cardiology | 2024年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Treatment with the glucagon-like peptide 1 receptor agonist semaglutide, administered subcutaneously at a dose of 2.4 mg once per week, reduces the risk of major cardiovascular events by 20% compared with placebo in patients who are overweight or obese and with pre-existing cardiovascular disease but without diabetes mellitus, according to findings from the SELECT trial.
引用
收藏
页码：69 / 69
相关论文
共 50 条
  • [1] SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes
    Fernandez-Ruiz, Irene
    NATURE REVIEWS CARDIOLOGY, 2024, 21 (02) : 69 - 69
  • [2] Weight loss with semaglutide in people with and without diabetes
    Kahl, S.
    DIABETOLOGIE, 2022, 18 (08): : 907 - 910
  • [3] Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
    Ryan, Donna H.
    Lingvay, Ildiko
    Deanfield, John
    Kahn, Steven E.
    Barros, Eric
    Burguera, Bartolome
    Colhoun, Helen M.
    Cercato, Cintia
    Dicker, Dror
    Horn, Deborah B.
    Hovingh, G. Kees
    Jeppesen, Ole Kleist
    Kokkinos, Alexander
    Lincoff, A. Michael
    Meyhoefer, Sebastian M.
    Oral, Tugce Kalayci
    Plutzky, Jorge
    van Beek, Andre P.
    Wilding, John P. H.
    Kushner, Robert F.
    NATURE MEDICINE, 2024, 30 (07) : 2049 - 2057
  • [4] Semaglutide Improved Cardiovascular Health in People Without Diabetes
    Harris, Emily
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (23): : 2241 - 2242
  • [5] Circulating MicroRNA-19 and cardiovascular risk reduction in response to weight-loss diets
    Xue, Qiaochu
    Heianza, Yoriko
    Li, Xiang
    Wang, Xuan
    Ma, Hao
    Rood, Jennifer
    Dorans, Kirsten S.
    Mills, Katherine T.
    Liu, Xiaowen
    Bray, George A.
    Sacks, Frank M.
    Qi, Lu
    CLINICAL NUTRITION, 2024, 43 (03) : 892 - 899
  • [6] Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
    Lingvay, Ildiko
    Brown-Frandsen, Kirstine
    Colhoun, Helen M.
    Deanfield, John
    Emerson, Scott S.
    Esbjerg, Sille
    Hardt-Lindberg, Soren
    Hovingh, G. Kees
    Kahn, Steven E.
    Kushner, Robert F.
    Lincoff, A. Michael
    Marso, Steven P.
    Fries, Tea Monk
    Plutzky, Jorge
    Ryan, Donna H.
    OBESITY, 2023, 31 (01) : 111 - 122
  • [7] Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity
    Mares, Adriana C.
    Chatterjee, Saurav
    Mukherjee, Debabrata
    CURRENT OPINION IN CARDIOLOGY, 2022, 37 (04) : 350 - 355
  • [8] SELECT semaglutide to improve outcomes in patients with obesity and cardiovascular disease, also without diabetes
    Gajos, Grzegorz
    CARDIOLOGY JOURNAL, 2024, 31 (05) : 782 - 783
  • [9] Impact of surgical and nonsurgical weight loss on diabetes resolution and cardiovascular risk reduction
    Katherine E. Nori Janosz
    Kerstyn C. Zalesin
    Wendy M. Miller
    Peter A. McCullough
    Barry A. Franklin
    Current Diabetes Reports, 2009, 9 : 223 - 228
  • [10] Impact of surgical and nonsurgical weight loss on diabetes resolution and cardiovascular risk reduction
    Janosz, Katherine E. Nori
    Zalesin, Kerstyn C.
    Miller, Wendy M.
    McCullough, Peter A.
    Franklin, Barry A.
    CURRENT DIABETES REPORTS, 2009, 9 (03) : 223 - 228
12345